A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD ®

Autor: Bonanni, Paolo, Cohet, Catherine, Kjaer, Susanne K., Latham, Nina B., Lambert, Paul-Henri, Reisinger, Keith, Haupt, Richard M.

Publikováno v: In Vaccine 2010 28(30):4719-4730

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard.

Autor: Halfon, Philippe^1,2 philippe.halfon@alphabio.fr, Ravet, Sophie³, Khiri, Hacène¹, Penaranda, Guillaume^1,2,3, Lefoll, Carole²

Publikováno v: Clinical Medicine Insights: Case Reports. 2010, Issue 3, p69-71. 3p.

Incident HPV 51 Infection after Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard®

Autor: Hacène Khiri, Philippe Halfon, Sophie Ravet, Guillaume Penaranda, Carole Lefoll

Publikováno v: Clinical Medicine Insights: Case Reports, Vol 2010, Iss 3, Pp 69-71 (2010)
Clinical Medicine Insights: Case Reports, Vol 3 (2010)
Clinical Medicine Insights. Case Reports

We report the case of a 19-year-old woman who received a complete vaccine program by Gardasil. After one year, Greiner HPV test revealed HPV51 positivity. This case report highlights the limits of the vaccine, and the need to have a clinical follow u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::434b75edac029c7a6b3fb138151f9168
https://doi.org/10.4137/ccrep.s6177

Impact and effectiveness of the quadrivalent human papillomavirus vaccine:A systematic review of 10 years of real-world experience

Autor: Rosybel Drury, Christine Velicer, Stan L. Block, Gonzalo Perez, Alfred J. Saah, Darron R. Brown, Rituparna Das, Géraldine Dominiak-Felden, Barbara J. Kuter, Brianna Lindsay, Mark J. DiNubile, Suzanne M. Garland, Nubia Muñoz, Susanne K. Kjaer

Publikováno v: Garland, S M, Kjaer, S K, Muñoz, N, Block, S L, Brown, D R, Dinubile, M J, Lindsay, B R, Kuter, B J, Perez, G, Dominiak-Felden, G, Saah, A J, Drury, R, Das, R & Velicer, C 2016, ' Impact and effectiveness of the quadrivalent human papillomavirus vaccine : A systematic review of 10 years of real-world experience ', Clinical Infectious Diseases, vol. 63, no. 4, pp. 519-527 . https://doi.org/10.1093/cid/ciw354
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

This systematic review assessed the global impact and effectiveness of quadrivalent human papillomavirus (HPV) vaccination on HPV infection and disease in real-world settings over a decade of use. Substantial reductions in HPV 6/11/16/18 infection, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1caf984f79525c586c4f044891a87b92
https://curis.ku.dk/ws/files/179126855/ciw354_1_.pdf

Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women.

Autor: McCormack, Paul L.¹ email@adis.co.nz, Joura, Elmar A.²

Publikováno v: BioDrugs. 2011, Vol. 25 Issue 5, p339-343. 5p.